Company Overview
Pulmatrix, Inc. operates as a biopharmaceutical entity dedicated to the development of novel inhaled therapeutic products designed to prevent and treat migraine and respiratory diseases that possess unmet medical needs within the United States. The company leverages its proprietary iSPERSE platform, an engineered dry powder delivery system, which facilitates the efficient administration of these specialized treatments to patients requiring targeted pulmonary or systemic delivery. This biotechnology firm functions within the broader Healthcare sector, specifically focusing on the Biotechnology industry, a classification that typically involves high-risk research and development with significant potential for breakthrough therapies but also substantial capital requirements. Currently, Pulmatrix, Inc. maintains a market capitalization of $4.97 million and employs 2 individuals, indicating a very small-scale operation typical of early-stage or late-preclinical biotechnology ventures. The combination of a sub-$5 million market cap and zero reported annual revenue suggests the company is in a pre-commercialization phase where financial resources are primarily allocated toward R&D and operational infrastructure rather than generating sales.
Financial Health
The company reports N/A for revenue over the trailing twelve months, while its net income stands at $-5,162,000 and EBITDA is recorded at $-5,063,000. The complete absence of revenue paired with significant negative net income reveals a cost structure entirely driven by operating expenses rather than cost of goods sold, as no sales exist to offset these expenditures. Pulmatrix, Inc. generated free cash flow of $-3,447,625, a figure that indicates the company is consuming its cash reserves to fund its development pipeline without any cash inflow from commercial operations. This negative free cash flow position necessitates ongoing capital raises or the utilization of existing cash balances to maintain solvency and continue research activities. The company's margins reflect its lack of commercial activity, with a gross margin of 0.0%, an operating margin of 0.0%, and a profit margin of 0.0%, all of which are mathematically zero due to the division by zero revenue. In terms of liquidity and leverage, the company holds $4.09 million in cash with N/A for total debt, resulting in a debt-to-equity ratio of N/A and a current ratio of 12.55. The substantial current ratio of 12.55 indicates an extremely strong short-term liquidity position relative to current liabilities, suggesting the company can easily cover its immediate obligations without needing external financing. Regarding return metrics, the return on equity is -80.9% and the return on assets is -45.9%, figures that demonstrate the company is currently destroying shareholder value due to heavy losses rather than generating returns.
Valuation Assessment
Pulmatrix, Inc. does not have a trailing P/E ratio as it is listed as N/A due to negative earnings, while its forward P/E is calculated at -0.30. The discrepancy between the non-existent trailing P/E and the negative forward P/E implies that the market is pricing in expectations of future profitability that have not yet been realized in historical earnings data. The stock trades at a price-to-book ratio of 1.30, which indicates that the market values the company at 30% above its net asset value, a premium often seen in biotechnology firms with valuable intellectual property despite current losses. Alternative valuation metrics such as the price-to-sales ratio are listed as N/A because there is no sales data, and the enterprise value-to-EBITDA stands at -0.17, reflecting the company's negative earnings profile. The stock has experienced significant volatility, trading between a 52-week high of $9.37 and a 52-week low of $1.32, with the current price position fluctuating within this wide range. The company possesses a beta of 1.73, which signifies that the stock price is substantially more volatile than the broader market, moving approximately 73% more aggressively in response to market changes.
Growth & Income
Pulmatrix, Inc. reports N/A for revenue growth year-over-year and N/A for earnings growth year-over-year, reflecting a stage where historical growth rates are not yet calculable due to a lack of comparable prior period revenue. Since the company has not generated revenue, the comparison between earnings growth and revenue growth is not applicable, as the primary focus remains on advancing clinical trials rather than scaling commercial operations. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning it does not distribute cash to shareholders but instead retains all available capital to fund its development efforts. Consequently, the company's overall growth and income profile is characterized by a reinvestment strategy where all financial resources are directed toward R&D and operational expansion rather than providing current income to investors.